These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 22845402)

  • 41. Anticancer Drug Combinations, How Far We can Go Through?
    Lu DY; Chen EH; Wu HY; Lu TR; Xu B; Ding J
    Anticancer Agents Med Chem; 2017; 17(1):21-28. PubMed ID: 27039923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Crossroad between linear and nonlinear transcription concepts in the discovery of next-generation sequencing systems-based anticancer therapies.
    Roukos DH
    Drug Discov Today; 2016 Apr; 21(4):663-73. PubMed ID: 26912452
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prioritizing therapeutic targets using patient-derived xenograft models.
    Lodhia KA; Hadley AM; Haluska P; Scott CL
    Biochim Biophys Acta; 2015 Apr; 1855(2):223-34. PubMed ID: 25783201
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Precision cancer medicine: the future is now, only better.
    Tsimberidou AM; Eggermont AM; Schilsky RL
    Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
    [TBL] [Abstract][Full Text] [Related]  

  • 46. More Than One Way to Measure? A Casuistic Approach to Cancer Clinical Trials.
    Andreoletti M
    Perspect Biol Med; 2018; 61(2):174-190. PubMed ID: 30146517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics.
    Lee AJ; Swanton C
    Biochem Pharmacol; 2012 Apr; 83(8):1013-20. PubMed ID: 22192819
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Implementing Genome-Driven Oncology.
    Hyman DM; Taylor BS; Baselga J
    Cell; 2017 Feb; 168(4):584-599. PubMed ID: 28187282
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products.
    Zhou Y; Peng S; Wang H; Cai X; Wang Q
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674402
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanisms of acquired resistance to targeted cancer therapies.
    Lackner MR; Wilson TR; Settleman J
    Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Getting the details right: gene signatures for cancer therapy.
    Master SR
    Clin Chem; 2010 Sep; 56(9):1378-80. PubMed ID: 20592045
    [No Abstract]   [Full Text] [Related]  

  • 52. The SHIVA01 trial: what have we learned?
    Le Tourneau C; Kamal M; Bièche I
    Pharmacogenomics; 2017 Jun; 18(9):831-834. PubMed ID: 28594293
    [No Abstract]   [Full Text] [Related]  

  • 53. Monitoring Trastuzumab Resistance and Cardiotoxicity: A Tale of Personalized Medicine.
    Dokmanovic M; Wu WJ
    Adv Clin Chem; 2015; 70():95-130. PubMed ID: 26231486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification.
    Fu S; Liu X; Luo M; Xie K; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2017 Apr; 14(4):351-362. PubMed ID: 28276747
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of genomics on personalized cancer medicine.
    Arteaga CL; Baselga J
    Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.
    Collins DC; Sundar R; Lim JSJ; Yap TA
    Trends Pharmacol Sci; 2017 Jan; 38(1):25-40. PubMed ID: 27871777
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genomics, personalized medicine, and supportive cancer care.
    Sonis ST
    Am Soc Clin Oncol Educ Book; 2015; ():9-16. PubMed ID: 25993135
    [No Abstract]   [Full Text] [Related]  

  • 58. The Emerging Role of Proteomics in Precision Medicine: Applications in Neurodegenerative Diseases and Neurotrauma.
    Alaaeddine R; Fayad M; Nehme E; Bahmad HF; Kobeissy F
    Adv Exp Med Biol; 2017; 1007():59-70. PubMed ID: 28840552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 4th international conference on tumor progression and therapeutic resistance: meeting report.
    Prabhu VV; El-Deiry WS
    Cancer Biol Ther; 2015; 16(3):363-76. PubMed ID: 25782066
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epigenome-based personalized medicine in human cancer.
    Yan W; Herman JG; Guo M
    Epigenomics; 2016 Jan; 8(1):119-33. PubMed ID: 26344672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.